---
document_datetime: 2023-09-21 18:08:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/novorapid-epar-procedural-steps-taken-authorisation_en.pdf
document_name: novorapid-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4323419
conversion_datetime: 2025-12-21 11:49:00.558335
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## I BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Novo Nordisk A/S, Denmark submitted on 14 August 1998 to the European Agency for the Evaluation of Medicinal Products (EMEA), an application to obtain a marketing authorisation in accordance  with  the  Centralised  Procedure  for  the  medicinal  product  NovoRapid  (insulin  aspart) falling within the scope of Part A of the Annex to Council Regulation No (EC) 2309/93.

The CPMP appointed the Rapporteur and Co-Rapporteur as follows:

Rapporteur:

## Licensing status:

The product was not licensed in any country inside or outside the EU at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 18 September 1998.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 27 November 1998.
- The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 1 December 1998.
- During  its  meeting  on  26-28  January  1999,  the  CPMP  agreed  on  the  consolidated  list  of questions to be sent to the applicant on 27 January 1999.
- The applicant submitted the responses to the consolidated list of questions on 10 February 1999.
- During  its  meeting  on  23-25  March  1999,  the  CPMP  agreed  on  a  list  of  questions  to  be addressed by an expert meeting on preclinical issues of insulin aspart.
- The Rapporteur and the Co-Rapporteur circulated the joint response assessment report on the applicant's responses to the list of questions to all CPMP members on 7 April 1999.
- The expert meeting on preclinical issues was held on 19 April 1999.
- During its meeting on 20-22 April 1999, the CPMP agreed on a list of outstanding quality issues to be addressed by the company in writing.
- The applicant submitted the responses to the outstanding issues on 22 April 1999.
- A report from the Expert meeting on preclinical issues of insulin aspart was circulated to all CPMP members on 12 May 1999.
- The  Rapporteur  circulated  a  further  assessment  report,  taking  into  account  the  company's responses on the outstanding quality issues, to all CPMP members on 12 May 1999.
- The applicant agreed to submit additional information regarding clinical data within the defined timeframe as indicated in the letter annexed to this assessment report, dated 19 May 1999.
- During the meeting on 18-20 May 1999 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation for the different NovoRapid presentations on 20 May 1999.

1/1

Dr. Per Sj√∂berg

Co-Rapporteur:

Dr. Gorm Jensen